docetaxel anhydrous has been researched along with Adverse Drug Event in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (18.06) | 29.6817 |
| 2010's | 53 (73.61) | 24.3611 |
| 2020's | 6 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Dimitsaki, S; Jaulent, MC; Natsiavas, P | 1 |
| Saito, Y | 1 |
| Galsky, MD; Martini, A; Montorsi, F; Oh, WK; Parikh, AB; Sfakianos, JP; Tsao, CK | 1 |
| Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW | 1 |
| Corman, S; Drea, E; Flannery, K; Gao, X; Hudspeth, L; Miao, R; Xue, M | 1 |
| Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J | 2 |
| Amin, M; Chiorean, EG; Gandhi, J; Harris, WP; Kim, R; Portnoy, D; Rocha-Lima, CMS; Song, T | 1 |
| Adamo, V; Battaglia, A; Berenato, R; Franchina, T; Giordano, A; Ricciardi, GRR; Russo, A; Scimone, A | 1 |
| Bandapalli, OR; Campo, C; da Silva Filho, MI; Försti, A; Goldschmidt, H; Hemminki, K; Mahmoudpour, SH; Merz, M | 1 |
| Boher, JM; Braamse, AMJ; Buffart, LM; Dekker, J; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Konings, IRHM; Marino, P; Oudard, S; Schuurhuizen, CSEW; Soulie, M; Verheul, HMW | 1 |
| Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| de Freitas, HM; Hadi, M; Hall, F; Ito, T; Kerr, C; Lanar, S; Lloyd, AJ; Nafees, B; Penton, J; Pham, TP | 1 |
| Augusto, SB; Baston, MT; D'Almeida Preto, D; De Marchi, PRM; de Oliveira, MA; Dias, JM; Geraige, CC; Mamere, AE; Paiva, BSR; Paiva, CE; Pinto, GDJ | 1 |
| do Brasil Costa, VI; Jorge, RV; Nobre, FF; Paula, DP | 1 |
| Chen, X; Liu, Y; Wang, Y; Zhang, T; Zhou, R; Zhu, J | 1 |
| Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Suzuki, K; Tsukube, S | 1 |
| Fukushima, H; Mitani, H; Nakano, K; Sasaki, T; Seto, A; Shimbashi, W; Takahashi, S; Yonekawa, H | 1 |
| Böhm, K; Borgmann, H; Dotzauer, R; Haferkamp, A; Höfner, T; Jäger, W; Mager, R; Savko, O; Thomas, A; Thomas, C; Tsaur, I | 1 |
| Auerbach, E; Corman, JM; Dahl, K; Olgac, S; Porter, C; Vuky, J | 1 |
| Au, HJ; Bée, V; Chan, A; Crown, J; Eiermann, W; Ferrero, JM; Fornander, T; Glaspy, J; Lalla, D; Liu, MC; Mackey, J; Martin, M; Miller, DP; Pawlicki, M; Pienkowski, T; Pintér, T; Robert, NJ; Santana, MJ; Sehdev, S; Slamon, DJ | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| Ito, K; Kaiho-Sakuma, M; Kurosawa, H; Nagai, T; Nagase, S; Niikura, H; Otsuki, A; Otsuki, T; Shiga, N; Shigeta, S; Takano, T; Tanaka, S; Tokunaga, H; Toyoshima, M; Tsuji, K; Utsunomiya, H; Yaegashi, N; Yamaguchi, T | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Aliño, SF; Bosó, V; de la Cueva, H; Herrero, MJ; Marqués, MR; Megias, JE; Montalar, J; Palomar, L; Poveda, JL; Rojas, L; Santaballa, A | 1 |
| Aktas, B; Aydogdu, M; Feisel-Schwickardi, G; Höffkes, HG; Illmer, T; Janni, W; Loibl, S; Lübbe, K; Lück, HJ; Maass, N; Mehta, K; Nekljudova, V; Neunhöffer, T; Ober, A; Park-Simon, TW; Reinisch, M; Schumacher, C; Tomé, O; von Minckwitz, G; Wagner, H | 1 |
| Chen, LK; Hu, ZH; Huang, Y; Liu, JL; Ma, Y; Ma, YX; Wei, CL; Wu, X; Xu, F; Xue, C; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY; Zou, BY | 1 |
| Clemens, MR; Crown, J; Gartner, E; Gladkov, OA; Jie, F; Keating, A; Steinberg, J; Vladimirov, V | 1 |
| Adinolfi, MI; Bafile, A; Bruera, G; Cannita, K; Ciccozzi, A; Cocciolone, V; Ficorella, C; Mancini, M; Pelliccione, M; Penco, M; Ricevuto, E; Romano, S | 1 |
| Gu, X; Jia, S; Wei, W; Zhang, WH | 1 |
| Cathomas, R; De Bono, JS; Gillessen, S; Omlin, A; Rothermundt, C; Sartor, O; Shen, L; Su, Z | 1 |
| Akande, T; Bomalaski, JS; Diaz, M; Dutia, MP; Gandara, DR; Gong, IY; Kelly, K; Lara, PN; Li, T; Mahaffey, N; Pan, CX; Semrad, T; Thomson, JA; Tomlinson, BK | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Al-Batran, SE; Burmester, M; Hinke, A; Hofheinz, RD; Hozaeel, W; Hübner, A; Koenigsmann, M; Kuhl, R; Linsse, B; Pauligk, C; Tauchert, FK; Wiegand, J; Windemuth-Kieselbach, C; Zur Hausen, G | 1 |
| Rexer, H | 1 |
| Doki, Y; Hamakawa, T; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Basch, E; Corty, RW; Dusetzina, SB; Green, AK; Meeneghan, M; Milowsky, MI; Reeder-Hayes, KE; Wood, WA | 1 |
| Bae, SH; Baek, JH; Chae, YS; Kang, BW; Kim, JG; Kim, JY; Kim, MK; Lee, KH; Lee, SA; Ryoo, HM; Song, HS; Yoon, S | 1 |
| Adar, L; Avisar, N; Barash, S; Bondarenko, IN; Gladkov, O; Moiseyenko, V; Shparyk, Y | 1 |
| Breed, WP; Goey, SH; Komen, MM; Nortier, JW; Smorenburg, CH; van den Hurk, CJ; van der Hoeven, JJ; van der Ploeg, T | 1 |
| Bensfia, S; Buyse, M; Chan, A; Crown, J; Drevot, P; Eiermann, W; Hitier, S; Houé, V; Lindsay, M; Mackey, JR; Martin, M; Pieńkowski, T; Press, MF; Provencher, L; Sadeghi, S; Saleh, M; Sauter, G; Sehdev, S; Semiglazov, V | 1 |
| Han, HJ; Kang, RY; Kim, DW; Lee, JY; Lee, SH; Lee, YJ; Yoo, KS | 1 |
| Alibhai, SM; Aziz, S; Breunis, H; Manokumar, T; Timilshina, N | 1 |
| Greil, R; Menzel, C; Mlineritsch, B; Moik, M; Namberger, K; Reitsamer, R; Ressler, S; Stoll, M | 1 |
| Gerritsen, WR; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Mooijer, MP; Rijnders, AY; Smit, EF; van der Hoeven, JJ; van der Veldt, AA; Windhorst, AD | 1 |
| Akyol, F; Bakker, J; Cardenal, F; De Neve, W; Dupont, JM; Ricardi, U; Scagliotti, GV; Senan, S; Stigt, J; van Meerbeeck, JP; Vansteenkiste, J | 1 |
| Coffey, MC; Cohn, DE; Comins, C; Harrington, KJ; Melcher, A; Mettinger, KL; Nuovo, G; Pandha, HS; Phelps, M; Protheroe, A; Roulstone, V; Spicer, J; Twigger, K; Vile, R; White, CM | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Bennett, CL; Bookstaver, PB; Campbell, W; Garg, V; Norris, LB; Qureshi, ZP; Raisch, DW | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Akaza, H; Arai, Y; Fujita, R; Hashine, K; Hoshi, S; Kakehi, Y; Kanayama, HO; Miki, T; Miura, T; Mizokami, A; Nishimura, K; Nonomura, K; Nonomura, N; Ogawa, O; Ozono, S | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Tani, T; Umeda, T | 1 |
| Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J | 1 |
| He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H | 1 |
| Fujii, R; Hara, I; Inagaki, T; Kohjimoto, Y; Kuramoto, T; Matusmura, N; Nanpo, Y; Nishizawa, S; Sasaki, Y | 1 |
| Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
| Barrios, C; Crinò, L; Franke, FA; Grinsted, L; Jänne, PA; Jeannin, G; Pereira, JR; Shaw, AT; Smith, I; Smith, P; Vansteenkiste, J; Zazulina, V | 1 |
| Akakura, K; Ichikawa, T; Kamiya, N; Masai, M; Mikami, K; Nakatsu, H; Naya, Y; Nomura, K; Okano, T; Ooki, T; Ota, S; Sato, N; Suzuki, H; Ueda, T | 1 |
| Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB | 1 |
| Diepolder, H; Heinemann, V; Kenngotte, S; Stemmler, HJ | 1 |
| Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H | 1 |
| Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A | 1 |
| Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D | 1 |
| Fujita, H; Honjo, H; Hosokawa, K; Kato, Y; Kinoshita, Y; Kuroboshi, H; Mori, T; Nakata, Y; Watanabe, A; Yamaguchi, T; Yasuda, J | 1 |
| Chiba, T; Fukushima, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Mitsumori, M; Nishimura, T; Sakai, Y; Shimada, Y; Teramukai, S; Watanabe, G; Yanagihara, K; Yoshikawa, K | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Baggstrom, MQ; Fracasso, PM; Govindan, R; Lim, WT; Read, W | 1 |
| Lambert-Falls, R; Modugno, S | 1 |
| Attard, G; Blagden, SP; de Bono, JS; de Jonge, M; Fong, PC; Kitzen, J; Pronk, LC; Verweij, J; Zhi, J; Zugmaier, G | 1 |
| Atkins, JN; Crane, JM; Detterbeck, FC; Harper, HD; Hensing, TA; Moore, DT; Socinski, MA; Stinchcombe, TE; Willard, EM | 1 |
5 review(s) available for docetaxel anhydrous and Adverse Drug Event
| Article | Year |
|---|---|
[Clinical and Fundamental Approach for Chemotherapy-induced Adverse Effect Attenuation by Oncology Pharmacy Specialists].
Topics: Animals; Antineoplastic Agents; Antiporters; Cisplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Magnesium Sulfate; Medical Oncology; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pharmacists; Premedication; Rats; Specialization | 2020 |
Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
Topics: Adolescent; Adult; Aged; Androgen Antagonists; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Quality of Life; Young Adult | 2019 |
The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Survival Analysis | 2020 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Cohort Studies; Docetaxel; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Paclitaxel; Premedication; Taxoids; United States; United States Food and Drug Administration | 2011 |
34 trial(s) available for docetaxel anhydrous and Adverse Drug Event
| Article | Year |
|---|---|
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endothelins; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Peptide Fragments; Taxoids; Treatment Outcome | 2017 |
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Goserelin; Humans; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2018 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brazil; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quality of Life; Young Adult | 2019 |
Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer Vaccines; Cell Line, Tumor; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Neoadjuvant Therapy; Neoplasm Grading; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2015 |
Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Radiography; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Lymphatic Metastasis; Middle Aged; Naphthoquinones; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2015 |
Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2015 |
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydrolases; Male; Neoplasm Staging; Neoplasms; Polyethylene Glycols; Taxoids; Treatment Outcome | 2015 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2015 |
[Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostat
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma; Castration; Combined Modality Therapy; Dendritic Cells; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Placebo Effect; Prevalence; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2015 |
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2015 |
Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2015 |
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Fusion Proteins; Recombinant Proteins; Serum Albumin; Serum Albumin, Human; Taxoids | 2016 |
Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Prospective Studies; Scalp; Taxoids | 2016 |
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids | 2016 |
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Receptor, ErbB-2; Taxoids | 2009 |
Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.
Topics: Aged; Biological Transport; Carbon Radioisotopes; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Metabolic Clearance Rate; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiometry; Taxoids; Tomography, X-Ray Computed | 2010 |
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome; Tumor Burden | 2011 |
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunohistochemistry; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Reoviridae; Taxoids | 2010 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Topics: Adult; Aged; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Taxoids | 2013 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Taxoids; Treatment Outcome | 2002 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Greece; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Risk Assessment; Risk Factors; Sex Distribution; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Survival Analysis; Taxoids | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
A Phase I trial of weekly docetaxel and topotecan for solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Risk Factors; Taxoids; Topotecan; Treatment Outcome | 2008 |
Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Neutropenia; Paresthesia; Taxoids | 2007 |
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2007 |
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Survival Analysis; Taxoids | 2008 |
33 other study(ies) available for docetaxel anhydrous and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Transfer Learning for Early Prediction of Adverse Drug Reactions: Docetaxel and Alopecia in Breast Cancer as a Case Study.
Topics: Adverse Drug Reaction Reporting Systems; Alopecia; Breast Neoplasms; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Machine Learning | 2023 |
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Withholding Treatment | 2021 |
Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center.
Topics: Adult; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Zoledronic Acid | 2022 |
Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Agents, Phytogenic; Budgets; Computer Simulation; Cost Savings; Docetaxel; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Male; Managed Care Programs; Models, Economic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients.
Topics: Antineoplastic Agents; Biomarkers; Breast Neoplasms; China; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; India; Malaysia; Orosomucoid; Predictive Value of Tests; Prognosis; Stomatitis; Taxoids | 2018 |
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.
Topics: Adult; Aged; Biomarkers, Tumor; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Inflammation; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Treatment Outcome | 2018 |
Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Prospective Studies | 2018 |
Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Topics: Aged; Bortezomib; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Risk Factors; Taxoids; Vincristine | 2018 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Herpesvirus 4, Human; Humans; Liposomes; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids | 2018 |
Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer.
Topics: Abdominal Pain; Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Brazil; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Cytochrome P-450 CYP2B6; Diarrhea; Docetaxel; Doxorubicin; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Longitudinal Studies; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide | 2020 |
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Safety; Taxoids; Treatment Outcome | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2019 |
Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Kallikreins; Male; Middle Aged; Neoplasm Staging; Prognosis; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Severity of Illness Index | 2019 |
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leiomyosarcoma; Middle Aged; Sarcoma, Endometrial Stromal; Taxoids; Uterine Neoplasms | 2014 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
SNPs and taxane toxicity in breast cancer patients.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cytochrome P-450 CYP3A; DNA-Binding Proteins; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Mucositis; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2014 |
Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Polyethylene Glycols; Taxoids | 2015 |
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Topics: Alopecia; Clinical Trials as Topic; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Dysgeusia; Humans; Male; Nail Diseases; Peripheral Nervous System Diseases; Prospective Studies; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
Topics: Aged; Antineoplastic Agents; Diarrhea; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms; Patient Selection; Prospective Studies; Quality of Life; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome; Vomiting | 2015 |
Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Topics: Adult; Aged; Cisplatin; Docetaxel; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Premedication; Retrospective Studies; Taxoids | 2017 |
A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Decision Support Techniques; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Judgment; Male; Neoplasm Metastasis; Oncologists; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Taxoids | 2017 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2013 |
Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2013 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Osteosarcoma; Prospective Studies; Taxoids | 2013 |
Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Estramustine; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.
Topics: Aged; Aged, 80 and over; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Gastrointestinal toxicity associated with weekly docetaxel treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Digestive System; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enterocolitis; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids | 2002 |
Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Granulocyte Precursor Cells; Leukocytes; Male; Mice; Mice, Inbred ICR; Neoplasm Metastasis; Radiometry; Taxoids; Time Factors | 2004 |
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Incidence; Lung Diseases; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2007 |